Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian equity markets recover
Fri, 18 Jul 11:30 am

After opening in the red, the Indian equity markets have made some recovery in last two hours of trade. However they continue to trade below the dotted line during morning session. Majority of sectoral indices are trading in red with realty and power sector being the leading losers in the pack. Only stocks from IT sector are in demand today.

The BSE-Sensex is trading down 10 points. The NSE-Nifty is trading down 6 points. The BSE Mid Cap index is trading down 0.1% and the BSE Small Cap index is trading up 0.2%. The rupee is trading at 60.32 to the US dollar.

Market regulator SEBI has finalised the draft norms for Infrastructure investment trusts. Taking forward a proposal made in the Union Budget, SEBI draft guidelines for Infrastructure Investment Trusts (InvITs) will enable creation of a new investment product for arranging long-term financing for infrastructure projects. The InvITs will receive tax benefits and can invest in PPP infra projects. These instruments can also be listed on stock exchanges. The norms state that the underlying assets of the InvITs should not be less than Rs 5 bn and the offer size, in case of a listing, should not be less than Rs 2.5 bn. InvITs will have a tax efficient pass through status for PPP and other infrastructure projects and holds the potential to give a boost to the struggling infra sector in the country.

Majority of Indian pharma stocks are trading in red, with Wockhardt Ltd and Strides Arcolab are leading the losers. As per the financial daily, Cipla Ltd, Emcure Ltd and Aurobindo pharma have signed sub-licensing agreements with UN backed medicines patent pool (MPP) for the manufacture of generic drugs viz; atazanavir and dolutegravir. The three Indian companies are among seven global companies to sign this agreement. The companies will be supplying the said drugs in various developing markets. As per MPP's executive director Greg Perry, Increased generic competition will help in reducing prices of the drugs and thus allowing national treatment programme to make available more number of drugs and thus helping more patients. While the Indian companies will benefit from the supply programme, however by nature the ARVs supplied under tenders or agreements to government or non-government agencies tend to offer lower margins.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian equity markets recover". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.